Get started
Author

Marcel A. Deken

Observed names: Deken, Marcel A, M.A. Deken, Marcel Deken
ORCID: 0009-0005-7324-7631
Observed ORCID: 0009-0005-7324-7631
OpenAlex ID: A5037222040
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
2016 · Marcel A. Deken, Jules Gadiot, et al. · OncoImmunology · 156
PDF
Variation of Neisseria gonorrhoeae Lipooligosaccharide Directs Dendritic Cell–Induced T Helper Responses
2009 · Sandra J. van Vliet, Liana Steeghs, et al. · PLoS Pathogens · 89
PDF
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma
2016 · Paula Kroon, Jules Gadiot, et al. · Cancer Immunology Immunotherapy · 34
PDF
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
2023 · M.A. Deken, K. Niewola-Staszkowska, et al. · Immuno-Oncology Technology · 27
PDF
Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity
2013 · Christian Blank, Jules Gadiot, et al. · OncoTargets and Therapy · 14
PDF
Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
2024 · Fanny Volat, Ragini Medhi, et al. · Molecular Cancer Therapeutics · 12
PDF
Autotaxin Inhibition with IOA-289 Decreases Breast Tumor Growth in Mice Whereas Knockout of Autotaxin in Adipocytes Does Not
2023 · Xiaoyun Tang, Andrew J. Morris, et al. · Cancers · 12
PDF
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib
2023 · Lars van der Veen, Michael Schmitt, et al. · International Journal of Toxicology · 8
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
2024 · Davide Melisi, Alberto Quinzii, et al. · Journal of Clinical Oncology · 5
PDF
Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice
2016 · Marcel Deken, Ji-Ying Song, et al. · International Journal of Molecular Sciences · 4
PDF
Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)
2017 · E.A. Rozeman, M.A. Deken, et al. · Annals of Oncology · 3
PDF
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
2026 · Maciej Garczyk, Gonçalo Outeiro-Pinho, et al. · Cell Reports · 2
922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models
2021 · Marcel Deken, Karolina Niewola, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
2026 · Maciej Garczyk, Gonçalo Outeiro-Pinho, et al. · Cell Reports · 1
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS
2024 · Nandini Ramachandra, Charan Thej Reddy Vegivinti, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
Validation of an LC–MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial
2022 · M. Mameli, J. Franchi, et al. · Journal of Pharmaceutical and Biomedical Analysis · 1
Abstract 1877: IOA-237 - A potent anti-CD73 mAb demonstrates monotherapeutic and combination efficacy in solid tumor models
2021 · Marcel A. Deken, Alan M. Carruthers, et al. · Cancer Research · 1
Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)
2017 · E.A. Rozeman, M.A. Deken, et al. · Annals of Oncology · 1
PDF
453P Proteomic evidence of on-target activity of cambritaxestat (IOA-289) in patients with metastatic pancreatic ductal adenocarcinoma
2026 · D. Melisi, G. Di Conza, et al. · Annals of Oncology
PDF
200P Patient tumor profiling supports the antitumor activity of the autotaxin inhibitor cambritaxestat (IOA-289) as monotherapy and in combination with standard of care in hepatocellular carcinoma and cholangiocarcinoma
2026 · A. Bevilacqua, M.A. Deken, et al. · Annals of Oncology
PDF
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.
2026 · Garczyk, Maciej, Outeiro-Pinho, Gonçalo, et al. · Open Access CRIS of the University of Bern
Supplementary Figure S1 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
2025 · Fanny Volat, Ragini Medhi, et al.
Supplementary Figure S4 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
2025 · Fanny Volat, Ragini Medhi, et al.
Supplementary Figure S5 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
2025 · Fanny Volat, Ragini Medhi, et al.
Data from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
2025 · Fanny Volat, Ragini Medhi, et al.
Works count: 33
Citation count: 373
H-index: 8
I10-index: 7
Year
Topic
Type